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Advanced biliary tract
cancerAbstract Background: Since sorafenib has shown activity in different tumour types and gem-
citabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated
ﬁrst-line gemcitabine plus sorafenib in a double-blind phase II study.liklinik,







Hif1aPatients and methods: 102 unresectable or metastatic BTC patients with histologically proven
adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology
Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, ﬁrst 7-
weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice
daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour
samples were prospectively stained for sorafenib targets and potential biomarkers. Serum
samples (ﬁrst two cycles) were measured for vascular endothelial growth factors (VEGFs),
vascular endothelial growth factor receptor 2 (VEGFR-2) and stromal cell-derived factor 1
(SDF1)a by enzyme-linked immunosorbent assay (ELISA).
Results: Gemcitabine plus sorafenib was generally well tolerated. Four and three patients
achieved partial responses in the sorafenib and placebo groups, respectively. There was no dif-
ference in the primary end-point, median progression-free survival (PFS) for gemcitabine plus
sorafenib versus gemcitabine plus placebo (3.0 versus 4.9 months, P = 0.859), and no differ-
ence for median overall survival (OS) (8.4 versus 11.2 months, P = 0.775). Patients with liver
metastasis after resection of primary BTC survived longer with sorafenib (P = 0.019) com-
pared to placebo. Patients who developed hand-foot syndrome (HFS) showed longer PFS
and OS than patients without HFS. Two sorafenib targets, VEGFR-2 and c-kit, were not
expressed in BTC samples. VEGFR-3 and Hif1a were associated with lymph node metastases
and T stage. Absence of PDGFRb expression correlated with longer PFS.
Conclusion: The addition of sorafenib to gemcitabine did not demonstrate improved efﬁcacy
in advanced BTC patients. Biomarker subgroup analysis suggested that some patients might
beneﬁt from combined treatment.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Most patients with biliary tract cancer (BTC) present
with unresectable disease [1] and their prognosis remains
bleak, with median overall survival (OS) times of
approximately 6 months and 5-year survival rates of
<5% for patients with advanced or metastatic disease.
Chemotherapy has been used to control disease,
improve survival and quality of life (QoL) in unresec-
table, recurrent or metastatic BTC, but OS rates of
P10 months remain diﬃcult to achieve, even with triple
combinations [2]. Phase II studies have reported that
gemcitabine alone is active and well tolerated, with
response rates of 8–60% [3]. In the ABC-02 phase III
trial, gemcitabine combined with cisplatin prolonged
progression-free survival (PFS) and OS compared with
gemcitabine alone [4]. Similar ﬁndings were also
reported for the Japanese BT22 study [5].
Understanding the molecular pathways in BTC has
provided the basis for the use of targeted therapies to
improve clinical outcome [6–9]. Bile acids have complex
eﬀects on the development of cholangiocarcinoma, with
activation of the epidermal growth factor receptor
(EGFR) leading to enhancement of the mitogen-acti-
vated protein kinase (MAPK) cascade [10]. Addition-
ally, several molecular and genetic alterations have
been reported [8]. The most frequent is disruption of
the MAPK pathway as a result of RAS or BRAF muta-
tions [11]. Proinﬂammatory and angiogenic molecules,
such as vascular endothelial growth factor (VEGF),
are also overexpressed in BTC tissue, stimulated by both
paracrine and autocrine mechanisms [12,13].Sorafenib is an oral multi-tyrosine kinase inhibitor
with reported activity in a variety of tumour types and
is approved for the treatment of advanced human hepa-
tocellular carcinoma (HCC) [14]. In a preclinical model,
growth of human BTC cells was suppressed by sorafenib
alone or in combination [15,16].
The activity of sorafenib alone or in combination
with gemcitabine in HCC has been demonstrated
[14,17–19], but, at the time the trial was planned, a ran-
domised phase III study of gemcitabine combinations in
the treatment of advanced BTC was lacking. Given this
concern, gemcitabine alone was chosen as the standard
treatment comparator [4,20] in a double-blind placebo-
controlled setting.
2. Patients and methods
2.1. Patients
Patients were aged >18 years with histologically pro-
ven adenocarcinoma of the gallbladder or intrahepatic
bile ducts, not amenable to curative resection or with
hepatic BTC metastases. Patients had at least one mea-
surable lesion in a non-irradiated, non-photodynamic
therapy-treated area, an ECOG performance status
score of 0–2, life expectancy of >12 weeks, and adequate
bone marrow, liver and renal function. Patients were not
allowed to receive a prior (palliative) radio-/chemother-
apy. Concomitant treatment with any other anticancer
therapy and prior use of RAF-kinase, VEGF, MEK
or farnesyl transferase inhibitors was not permitted.
All patients provided written, informed consent.
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This randomised, double-blind phase II study aimed to
demonstrate a clinically meaningful outcome from addi-
tion of sorafenib to gemcitabine. The primary end-point
was PFS. Patients were randomised (1:1) to receive gem-
citabine plus sorafenib (sorafenib group) or gemcitabine
plus placebo (placebo group). Further details of study
design are presented as Supplementary Information.
The primary eﬃcacy population was the modiﬁed inten-
tion-to-treat (mITT) population comprising all patients
who received at least one dose of study medication. Sec-
ondary analyses were conducted in the per-protocol
(PP) population comprising all evaluable patients with-
out major protocol violations. If patients received subse-
quent anticancer therapy after study discontinuation but
before occurrence of progressive disease (PD) or death,
PFS was censored (see Supplementary Information).
Secondary end-points included safety, OS, best over-
all response (OR), stable disease duration, 1-year PFS
and OS rates and QoL (European Organisation for
Research and Treatment of Cancer (EORTC) QLQ-
C30 (version 3.0)). Safety variables comprised treat-
ment-emergent adverse events (AEs; coded according
to MedDRA 14.0 and 14.1; severity graded by NCI-
CTC v3.0), laboratory data, concomitant medications
and vital signs.
The study was approved by 11 German independent
ethics committees, met all regulatory requirements
(ClinicalTrials.gov: NCT00661830), and was conducted
in accordance with the Declaration of Helsinki.2.3. Treatment and tumour assessments
Gemcitabine (1000 mg/m2) was administered days 1,
8, 15, 22, 29, 36, 43 of the ﬁrst cycle (8 weeks’ duration)
and days 1, 8 and 15 of all subsequent cycles (4 weeks’
duration). Sorafenib (400 mg) or placebo tablets were
administered twice daily. Dose adjustments based on
patient tolerance were permitted. Evaluation of tumour
response according to Response Evaluation Criteria in
Solid Tumours (RECIST) 1.0 was conducted every
8 weeks and 30 days after end of treatment and com-
pared with baseline. Conﬁrmation by a repeat computed
tomography scan was required for complete or partial
responses. QoL was assessed on day 29 of the ﬁrst cycle
and day 1 of each subsequent cycle and results com-
pared by Wilcoxon rank-sum tests.2.4. Protein and serum analyses
Immunohistochemical (IHC) staining of paraﬃn-
embedded tumour sampleswas carried out in part to assess
the expression levels of VEGF-C and -D, VEGFR-2 and -
3, CXCR4, Hif1a, c-kit, PDGFRb and PTEN (Supple-
mentary Table 1) [21]. Overall, 51 patient samples wereobtained for assessment of VEGF-C and PTEN, 52 for
PDGFRb, 53 for VEGF-D, VEGFR-3, Hif1a, 56 for c-
kit, 58 for CXCR4 and 59 for VEGFR-2 by two indepen-
dent, blinded investigators. Staining was evaluated (no
staining 0, weak 1, moderate 2 and strong 3) and divided
into two groups: negative (0) and positive (weak–moder-
ate–strong) for statistical analysis. These biomarkers com-
ply with the REMARK guidelines. Serum samples were
tested in duplicate for SDF1a, VEGF-A, VEGF-D and
soluble (s) VEGFR-2 concentrations by quantitative
Duo-ELISA (R&D, Minneapolis). To explore associa-
tions between IHC results and clinical parameters, univar-
iate analyses were performed using Pearson’s Chi-2 test,
Cox regression and Fisher’s exact test.2.5. Statistical considerations
Assuming a median PFS of 3 months for the placebo
group and exponentially distributed time to event, 86
events were required to show a 50% improvement for
sorafenib, with 80% power and one-sided signiﬁcance
level of 15%. With 18 months recruitment 12 months
follow-up and allowing a 5% drop-out rate, 96 patients
were required to be randomised. The primary popula-
tion for eﬃcacy analysis was the modiﬁed intention-to
treat (mITT) population. The primary eﬃcacy end-point
was also analysed in per-protocol population.
To investigate associations between results of immu-
nohistochemistry for all markers and clinical-pathologi-
cal parameters, univariate statistical analyses were
performed using Pearson’s Chi-2 test, cox regression
and Fisher’s exact test. Duration of overall response
and duration of stable disease, PFS and OS were esti-
mated by Kaplan–Meier. Diﬀerences between treatment
groups for PFS and OS were tested by the one-sided log-
rank test. Post hoc Kaplan-Meier analyses for PFS and
OS were done according to tumour location and HFS.
Hazard ratios were estimated by Cox proportional haz-
ard model. Rates of PFS and OS 1 year after treatment
start and median length of PFS and OS were deter-
mined. For quality of life, scores of QLQ-C30 functional
scales, multi-item scales and single-item scales on day 29
of ﬁrst treatment cycle in each treatment group were
compared by Wilcoxon rank-sum tests.3. Results
3.1. Patient characteristics
Overall 102 patients were randomised (Fig. 1). The
mITT and safety populations were identical (sorafenib,
N = 49; placebo, N = 48). The PP population comprised
35 and 34 patients treated with sorafenib and placebo,
respectively (Supplementary Information). Demographic
and baseline characteristics were well balanced between
the two arms (Table 1). Comparably, 50% of patients
Fig. 1. CONSORT chart.
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dying from progression without further treatment was
51% for sorafenib and 54% for placebo. At the end of
the observation period, 84% patients treated with sorafe-
nib and 75% with placebo had died or progressed.
An average of 4.2 cycles of sorafenib and 5.0 cycles of
placebo treatment were completed. Median treatment
duration was 2.3 months (range 0–19.1) for sorafenib
and 4.2 months (range 0.3–21.4) for placebo. There were
fewer dose adjustments and treatment interruptions in
the placebo group.
3.2. Eﬃcacy
In the mITT population, patients receiving sorafenib
plus gemcitabine had a shorter median PFS than those
receiving gemcitabine alone (3.0 versus 4.9 months).
The corresponding log rank test was not statistically sig-
niﬁcant (P = 0.859). A Cox regression model with treat-ment as a covariate yielded a hazard ratio (HR) of 1.28
(95% conﬁdence interval (CI): 0.811–2.023) indicating a
28% increase in the risk of progression or death for
sorafenib (Table 2). A post-hoc analysis without censor-
ing of subsequent anticancer therapy showed similar
results (2.7 and 4.2 months, respectively, HR: 1.15;
95% CI: 0.741–1.770). The PP population conﬁrmed
the mITT analysis, with median PFS for sorafenib ver-
sus placebo of 3.2 versus 4.9 months (HR: 1.18, 95%
CI: 0.678–2.053). One-year PFS for sorafenib versus pla-
cebo was 16% versus 18% (mITT population) and 25%
versus 18% (PP population). The median OS times in
the mITT and PP populations were 8.4 and 10.8 months
for sorafenib versus 11.2 and 10.6 months for placebo
(mITT P = 0.775, HR: 1.20; 95% CI: 0.747–1.927; PP
P = 0.561, HR: 0.96, 95% CI: 0.538–1.699). Age proved
an independent negative prognostic factor for OS
(P = 0.014, HR: 1.044, 95%CI: 1.009–1.080) in a post-
hoc analysis.
Table 1
Demographic and baseline characteristics (modiﬁed intention-to-treat (mITT) population).
Parameter Gemcitabine + sorafenib(N = 49) Gemcitabine + placebo(N = 48)
Age, y, median (range) 64.0 (44–83) 64.5 (36–84)
Female, N (%) 20 (41) 23 (48)
Age, y, median (range) 64.0 (44–83) 64.5 (36–84)
Race, N (%)
European 49 (100) 48 (100)
Type of carcinoma, N (%)
Adenocarcinoma of gall bladder 6 (12) 7 (15)
Adenocarcinoma of intrahepatic bile ducts 33 (67) 29 (60)
Hepatic metastasesa 10 (20) 12 (25)
Grade, N (%)
1 (well diﬀerentiated) 2 (4) 0
2 (moderately diﬀerentiated) 23 (50) 30 (70)
3 (poorly diﬀerentiated) 20 (43) 13 (30)
4 (undiﬀerentiated) 1 (2) 0
ECOG performance status, N (%)
0 30 (64) 35 (80)
1 17 (36) 8 (18)
2 0 1 (2)
Target lesions
Unresected primary tumour, N 10 9
Size, mm, mean (SD) 82.3 (28.93) 95.7 (18.97)
Liverb, N 38 32
Liver hilus and/or lymph nodesb, N 21 13
Lung and/or soft tissueb, N 3 6
Patients with more than 1 lesion 31 31
Previous treatment
Surgery
Yes 25 (51) 26 (54)
No 24 (49) 22 (46)
Radiotherapy
Yes 47 (96) 46 (96)
No 2 (4) 2 (4)
Chemotherapy
Yes 1 (100) 1 (100)
Missing 48 47
Abbreviations: ECOG PS; Eastern Cooperative Oncology Group performance status; SD, standard deviation.
a Referring to study design: ‘hepatic metastases of a primary resected and histological proofed biliary tract cancer’.
b Target lesions of a BTC tumour.
Table 2
Progression-free survival (mITT population).
Gemcitabine + sorafenib (N = 49) Gemcitabine + placebo (N = 48)
Patients with death/progression, n (%) 41 (84) 36 (75)
Patients censored, N (%) 8 (16) 12 (25)
PFS, months, median (95% conﬁdence interval (CI)) 3 (1.8–7.2) 4.9 (3.5–7.7)
PFS at 1 year,% 16.4 17.6
HR (95% CI) for sorafenib versus placeboa 1.281 (0.811–2.023)
P-value (log-rank test) 0.8593
a Estimated by Cox proportional hazards model; PFS, progression-free survival; HR, hazard ratio; mITT, modiﬁed intention-to-treat.
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patients for sorafenib and placebo, respectively. Conﬁr-
mation of response turned out as challenging. Due to
the short treatment period of most patients, best
response data were missing and could not be conﬁrmed
in these data settings. With no complete responses, par-
tial response was achieved in four (14%) patients receiv-
ing sorafenib and three (10%) receiving placebo. In allevaluable patients, 86% of sorafenib and 90% of placebo
group reached at least stable disease. Kaplan–Meier esti-
mates of stable disease duration were 9.2 months
(sorafenib) and 7.7 months (placebo).
As BTC is a tumour with heterogeneous locations,
subgroup analyses showed on the one hand a better
PFS for patients with intrahepatic bile duct cancers in
the placebo group (P = 0,027, Fig. 2 A) and on the other
Fig. 2. Kaplan–Meier-curves for progression-free survival in relation
to the BTC localisation, with patients (A) with adenocarcinomata of
intrahepatic bile ducts and (B) with primarily hepatic metastases based
on BTC. BTC, biliary tract cancer; PFS, progression-free survival.
Fig. 3. Kaplan–Meier-curves for (A) OS and (B) progression-free
survival in relations to hand-foot syndrome in the sorafenib group. OS,
overall survival; PFS, progression-free survival.
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hepatic metastases of BTC (P = 0,019, Fig. 2 B). For OS
no diﬀerences could be detected.
Patients with hand-foot syndrome (HFS) were longer
under treatment as patients without HFS (P = 0.014). In
total, 17 (17%) patients developed hand-foot syndrome
(HFS) of which 15 (88%) were in the sorafenib group
(P = 0.001). The median PFS was 7.2 months (95% CI:
2.2–12.1) for HFS-positive versus 3.5 months (95% CI:
2.4–4.5) for HFS-negative patients (P = 0.096), and
median OS was 14.4 months (95% CI: 5.6–23.1) versus
10.2 months (95% CI: 6.6–13.8) (P = 0.288), respec-
tively. In the sorafenib group, 31% of patients developed
HFS with a median PFS of 7.2 months (95% CI: 4.3–
10.1) versus 1.9 months (95% CI: 1–2.8) for HFS-nega-
tive patients (P = 0.053) (Fig. 3).3.3. Safety and quality of life
All patients reported at least one AE during the
study. AEs possibly related to study treatment are
shown in Table 3. Serious AEs (SAE) occurred in 33
(67%) patients with sorafenib and 35 (73%) patients with
placebo. Seven SAEs in each group were judged to be
possibly related to study treatment. The most frequent
SAEs were cholangitis, fever and general health deterio-
ration. Fatigue, occurred in >50% of patients in both
groups, followed by thrombocytopenia. Major AE dif-
ferences between groups were nausea (sorafenib 29%,
placebo 56%), HFS (31% versus. 4%), weight loss
(24% versus. 10%), epistaxis (20% versus. 0%) and oral
disorder (20% versus. 2%). Eleven patients with s
(22%) and four patients with placebo (8%) died due to
Table 3
Adverse events possibly related to study treatments and occurring in P10% of patients in either treatment group (safety population).
Preferred term, patients Gemcitabine/placebo (% of N = 48) Gemcitabine/sorafenib (% of N = 49)
Grade (%)a 1–2 3–4 1–2 3–4
Fatigue 35.4 2.1 22.5 4.1
Thrombocytopenia 37.5 8.3 28.6 12.2
Hand-foot syndrome 4.2 0 16.3 14.3
Diarrhoea 8.3 0 30.6 2.0
Leukopenia 27.1 4.2 20.4 8.2
Rash 14.6 0 28.6 0
Oral disorder 0 0 20.4 0
Nausea 37.5 8.3 18.4 4.1
Alopecia 20.8 0 22.5 2.0
Anaemia 8.3 2.1 6.1 4.1
Stomatitis 0 0 12.2 0
Vomiting 12.5 2.1 12.2 4.1
Pruritus 2.1 0 10.2 2.0
Epistaxis 0 0 10.2 0
Fever 10.4 2.1 10.2 4.1
Neutropenia 8.3 8.3 4.1 4.1
Obstipation 10.4 0.0 4.1 0.0
a Grade 5 was only reached by one patient.
Table 4
Association between tumour biomarker expression and patient characteristics.














VEFD-C 51 Positive 8 25 50 25 25 50 25
Negative 92 11 72 17 0.378 38 49 13 >0.99
VEFD-D 53 Positive 57 13 67 20 43 40 17
Negative 43 9 70 22 0.685 26 61 13 0.224
VEGFR-2 59 Positive 2 No analyses
Negative 98
VEGFR-3 53 Positive 53 4 68 29 21 64 14
Negative 47 20 68 12 0.187 52 36 12 0.035
CXCR4 58 Positive 40 4 78 17 39 43 17
Negative 60 14 63 23 0.377 29 60 11 0.372
c-kit 56 Positive 0 No analyses
Negative 100
PDGFRb 52 Positive 27 0 93 7 36 64 0
Negative 73 16 61 24 0.153 37 45 18 0.746
Hif1a 53 Positive 9 60 40 0 80 20 0
Negative 91 8 71 21 0.024 31 54 15 0.144
PTEN 51 Positive 63 9 69 22 44 47 9
Negative 37 16 68 16 0.662 26 58 16 0.351
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sorafenib. One SAE (cause of death: toxic lung disor-
der), possibly related to gemcitabine, was reported for
placebo. Supplementary Table 2 shows QLQ-C30 scores
at baseline and day 29 and their changes in the groups.
Comparison between both groups on day 29 disclosed
that many items were in favour of placebo. However,
for cognitive function, dyspnoea and constipation,
scores between groups were quite similar; and nausea/
vomiting scores were even more favourable for
sorafenib.3.4. Biomarker analysis
Fifty-nine patient tumour samples were available for
analysis of the sorafenib target structures VEGFR-2 and
-3, PDGFRb and c-kit (Table 4). To depict the angio-
genic microenvironment, the ligands VEGF-C and -D,
Hif1a, CXCR4 and PTEN were analysed by IHC
(Table 4, Supplementary Fig. 1). For c-kit, VEGFR-2,
CXCR-4 and PTEN, no correlation was found with
any clinical or pathological parameters. The target
c-kit could not be detected in any BTC tumour tissue.
Fig. 4. Progression-free survival for PDGFRb subgroup (N = 52)
PFS, progression-free survival.
Fig. 5. Serum analysis of patients during the ﬁrst 8 weeks (A) DsVEGFR-
>90 days), (B) PFS (0–90 days and >90 days) of patients with hand-foot s
relation to their treatment arm and (D) PFS of the sorafenib treated grou
3132 M. Moehler et al. / European Journal of Cancer 50 (2014) 3125–3135VEGFR-2 expression was found in 32% of vessels in
close proximity to the tumour; however, only one
tumour was clearly positive for VEGFR-2. Hif1a was
expressed in 9% of all tumours. Higher T-stages (T3/4)
were associated with negative Hif1a (P = 0.024). VEG-
FR-3 was highly expressed in 53% (28/53) and particu-
larly in LN-positive patients (P = 0.035), and was co-
expressed together with VEGF-D in 57% of patients
(P = 0.011). PDGFR-b was detected in the tumour
stroma in 27% of patients. Independent of treatment,
PDGFR-b negative patients showed improved PFS
(P = 0.052, Fig. 4).
Serum analyses for biomarkers were performed in 49
patients during follow-up of at least two cycles (Fig. 5A–
D). Patients with a PFS of >90 days displayed a higher
sVEGFR-2 increase than those who progressed before
<90 days. DsVEGFR-2 increase was higher in the
HFS-subgroup (P < 0.008) with late progression. Fur-
thermore, in patients who received sorafenib and devel-
oped HFS, the DsVEGFR-2 increase was higher in late
progressive patients (P < 0.009). During the ﬁrst
8 weeks, patients presented no changes in SDF1a,
VEGF-A and -D levels.2 levels of all patients (N = 49) compared to their PFS (0–90 days and
yndrome (N = 13), (C) DsVEGFR-2 levels of all patients (N = 49) in
p with hand-foot syndrome (N = 11).
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Even if this trial did not meet its primary eﬃcacy end-
point and PFS in mITT and PP population were not sig-
niﬁcantly diﬀerent in patients receiving gemcitabine plus
or minus sorafenib, our study revealed important results
to be further discussed. Analysis of PFS in the PP popu-
lation supported the primary analysis. Treatment dura-
tion was not only shorter for sorafenib, but also fewer
dose adjustments and treatment interruptions occurred
in the placebo group.However, overall mean gemcitabine
doses were similar, suggesting that more patients had
early discontinuation of sorafenib, even without evidence
of higher grade toxicities. Consistent with this, a recent
survey of HCC patients showed that those receiving
half-dose sorafenib (200 mg twice daily) received longer
treatment than those receiving full-dose sorafenib [22].
Furthermore, a post-hoc analysis showed that the half-
dose sorafenib patients achieved longer survival times.
For any secondary eﬃcacy end-point, again no bene-
ﬁt favouring sorafenib plus gemcitabine over gemcita-
bine alone was observed. Best response was mostly
stable disease, with more than 85% of evaluable patients
in both groups. Thus, tumour control rates for both
groups were in the range of those reported for cis-
platin-gemcitabine in the ABC-02 trial, with a tumour
control rate of 81.4%, but higher than the gemcitabine
alone arm (71.8%) [4].
Safety results did not raise any concerns, with no
major diﬀerences in AEs or serious AEs, possibly related
to treatment. Overall, most AEs were consistent with
those previously identiﬁed as being associated with gem-
citabine or sorafenib administration [20]. Our QoL data
did not generally favour any treatment group. As HFS is
one of the most common AEs associated with sorafenib,
over 88% of all patients suﬀering HFS were in the
sorafenib group. We did an exploratory and hypothe-
sis-generating analysis on its correlation with survival
data. HFS occurred more frequently when patients were
treated longer with sorafenib, HFS-positive patients had
a PFS advantage of 3 months and an OS beneﬁt of
4 months. This positive trend was also found in the
sorafenib group with a beneﬁt for PFS and OS of 5
and 7 months. These results are similar to those
observed for PFS in metastatic renal cancer patients
[23] and compared well with other studies analysing
the presence of HFS as being predictive for better OS
and prolonged PFS in sorafenib-treated patients with
advanced HCC [17–19].
Clinical responses to targeted therapies such as
sorafenib have been shown to depend on the expression
levels of their target proteins in the tumour tissue [24].
The absence of sorafenib target proteins like c-kit and
VEGFR-2 in this study population as well as minor
expression levels of some biomarkers (27% PDGFRb)
in BTC may explain at least in part the low eﬃcacy ofthis combination treatment. Additionally, serum analy-
ses during the ﬁrst 8 treatment weeks indicated higher
DsVEGFR-2 levels in patients with longer PFS. Since
this soluble marker demonstrated some positive predic-
tive value, not only for sorafenib and HFS, but also
gemcitabine, sVEGFR-2 should be addressed in larger
studies as a potentially predictive marker for small mol-
ecules [25–27].
In the recent years, treatment options expanded for
BTC. Today, gemcitabine combined with platinum-
based agents are somewhat standard regimens [28].
Combinations with targeted therapies are still under
investigation. So far, addition of cetuximab did not
enhance activity of Gemcitabine/Oxaliplatin but was
well tolerated [28]. The BINGO phase 2 trial conﬁrmed
its good agreeability and led to encouraging antitumour
activity and secondary resections in a third of patients
[29]. Despite preclinical and clinical results reporting
the activity of sorafenib alone or in combinations in
HCC [14,17,22], in advanced BTC patients recent ﬁrst-
line and second-line phase II studies of sorafenib alone
failed to display objective responses and were associated
with low activity, respectively [30,31]. Studies involving
small molecules oﬀered mixed results. Sunitinib has
shown marginal second-line activity [32] and a phase
II trial of gemcitabine, oxaliplatin and bevacizumab
reported some antitumour activity and tolerable safety
in advanced BTC patients [33]. Recently, in a random-
ised phase III study, the addition of erlotinib to gemcit-
abine and oxaliplatin failed to show PFS beneﬁt
compared with chemotherapy alone [34]. Only the sub-
group of cholangiocarcinoma patients had a signiﬁ-
cantly prolonged PFS with erlotinib. It has been
suggested that a subset of BTC patients might beneﬁt
from dual target tyrosine kinase inhibitors, based on
KRAS mutation status, EGFR and HER2 signalling
[8,35]. In fact, localisation of metastases to the liver
seemed to be beneﬁcial in our trial, as these patients ben-
eﬁted from sorafenib compared to patients with adeno-
carcinoma of intrahepatic ducts.
In conclusion, this randomised, placebo-controlled
study did not provide evidence that adding sorafenib
to gemcitabine as ﬁrst-line chemotherapy improves out-
comes in unselected patients with advanced BTC. Fur-
ther prospective double-blind biomarker-driven phase
II trials are required to characterise targeted agents
added to standard chemotherapy to further improve
outcome in these patients with high medical need.5. Funding
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